米非司酮对子宫肌瘤组织中雌孕激素受体和表皮生长因子受体的影响  

Effects of mifipristone on ER?PR and EGF-R level in uterine leiomyoma

作　　者：李卫平[1] 严隽鸿[1] 林其德[1] 陈珠萍[1] 丁传伟[1] 

机构地区：[1]上海第二医科大学附属仁济医院妇产科,200001

出　　处：《中国实用妇科与产科杂志》2002年第1期30-32,共3页Chinese Journal of Practical Gynecology and Obstetrics

摘　　要：目的　探讨米非司酮对子宫肌瘤组织内雌、孕激素受体和表皮生长因子受体的影响。方法　 44例子宫肌瘤患者作全子宫切除或子宫肌瘤挖出术 ,其中米非司酮组 16例 ,术前予米非司酮 2 5mg ,每日 2次 ,连用 3个月 ;对照组 2 8例。采用免疫组化法测定子宫肌瘤及子宫平滑肌内雌、孕激素受体含量 ,用流式细胞仪测定EGF -R水平。结果　米非司酮组子宫肌瘤及子宫平滑肌内PR较对照组显著下降 (P <0 0 1) ,ER无显著差异 ;米非司酮组子宫肌瘤及子宫平滑肌EGF -R水平显著低于对照组 (P <0 0 1)。结论　子宫肌瘤内EGF -R减少是米非司酮治疗后子宫肌瘤缩小的重要机制 ,这一作用可能与米非司酮阻断孕酮与PR的结合有关。Objective To study the effects of mifipristone on estrogen receptor(ER),progesterone receptor(PR) and epidermal growth factor-receptor (EGF-R) in uterine leiomyoma.Methods Hysterectomy was performed in 44 patients with leiomyoma who were divided into study group(16 cases)that were administrated with mifipristone 25mg,twice a day for 3 months before operation, and control group(28 cases)that did not receive mifipristone.RE?PR and EGF-R level in leiomyoma and myometrium of two groups were determined respectively by immunochemistry and flow cytometry.Results PR and EGF-R level in leiomyoma and myometrium of study group significantly decreased compared with that of control group(P<0.01),there was no significant difference in ER between two groups.Conclusion The decrease of EGF-R in leiomyoma may be one of the important mechanisms of leiomyoma regression after treatment with mifipristone;this may be related with mifipristone that blocks the combination of progesterone with PR.

关 键 词：子宫平滑肌瘤 此激素受体 孕激素受体 米非司酮 表皮生长因子受体 

分 类 号：R979.22[医药卫生—药品] R737.33[医药卫生—药学]